Q-omics provides the consensus-scored C18orf63 profile across patient tissues and cancer cell-line models. C18orf63 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, C18orf63 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, C18orf63 RNA expression shows 6,688 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, LUAD, and STAD as cancer lineages where C18orf63 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C18orf63 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C18orf63 survival associations across molecular data types. C18orf63 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C18orf63 RNA expression–survival associations across cancer types. High C18orf63 expression shows unfavorable associations in BRCA, THCA, LUSC, TGCT, DLBC and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for C18orf63 RNA expression.
This table summarizes C18orf63 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C18orf63. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C18orf63 shows lower tumor expression in LUAD, KICH, LUSC and BRCA and higher tumor expression in KIRC and LIHC. The LUAD box plot shows higher C18orf63 RNA expression in normal versus tumor tissue (log2 FC = −0.309, t-test p < 0.001).
This table shows molecular features associated with C18orf63 in patient tissues and cancer cell lines. In patient samples, C18orf63 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, C18orf63 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
